Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 963-970

  Gore, Steven D ^a   Weng, Li Jun ^a   Figg, William D ^c   Zhai, Suoping ^c   Donehower, Ross C ^a   Dover, George ^b   Grever, Michael R ^a   Griffin, Constance ^a   Grochow, Louise B ^c   Hawkins, Anita ^a   Burks, Kathleen ^a   Zabelena, Yelena ^c   Miller, Carole B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; HISTONE DEACETYLASE; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOSTASIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; EDEMA; ENZYME INHIBITION; FATIGUE; FEVER; GRANULOCYTOPENIA; HUMAN; HYPERAMMONEMIA; HYPERCHOLESTEROLEMIA; HYPERURICEMIA; HYPOCALCEMIA; LIVER TOXICITY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; TREATMENT OUTCOME; URINE INCONTINENCE; VOMITING;

ACUTE DISEASE; AGED; APOPTOSIS; BONE MARROW CELLS; CELL CYCLE; COLONY-FORMING UNITS ASSAY; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; FETAL HEMOGLOBIN; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NAUSEA; PHENYLBUTYRATES; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 0036554808     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Warrell, R. P., Frankel, S. R., Miller, W. H., Jr., Scheinberg, D. A., Itri, L. M., Hittelman, W. N., Vyas, R., Ndreeff, M., Tafuri, A., Jakubowski, A., Gabrilove, J., Gordon, M. S., and Dmitrovsky, E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med., 324: 1385-1393, 1991.
2. Gore, S. D., Weng, L-J., Zhai, S., Figg, W. D., Donehower, R. C., Dover, G. J., Grever, M., Griffin, C. A., Grochow, L. B., Rowinsky, E. K., Zabalena, Y., Hawkins, A. L., Burks, K., and Miller, C. B. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Canc. Res., 7: 2330-2339, 2001.
3. DiGiuseppe, J. A., Weng, L-J., Yu, K. H., Fu, S., Kastan, M. B., Samid, D., and Gore, S. D. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia (Baltimore), 13: 1243-1253, 1999.
4. Gore, S. D., Samid, D., and Weng, L-J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin. Canc. Res., 3: 1755-1762, 1997.
5. Yu, K. H., Weng, L-J., Fu, S., and Gore, S. D. Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all trans-retinoic acid. Leukemia (Baltimore), 13: 1258-1265, 1999.
6. Redner, R. L., Wang, J., and Liu, J. M. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood, 94: 417-428, 1999.
7. Silverman, L. R., Holland, J. F., Weinberg, R. S., Alter, B. P., Davis, R. B., Ellison, R. R., Demakos, E. P., Cornell, C. J., Jr., Carey, R. W., Schiffer, C., and et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia, 7 (Suppl. 1): 21-29, 1993.
8. Piscitelli, S. C., Thibault, A., Figg, W. D., Tompkins, A., Headlee, D., Lieberman, R., Samid, D., and Myers, C. E. Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J. Clin. Pharmacol., 35: 368-373, 1995.
9. Loken, M. R., Shah, V. O., Dattilio, K. L., and Civin, C. I. Flow cytometric analysis of human bone marrow: II. Normal B lymphocyte development. Blood, 70: 1316-1324, 1987.
10. Dover, G. J., Brusilow, S., and Charache, S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood, 84: 339-343, 1994.
11. Ishiguro, K., and Sartorelli, A. C. Coinduction of embryonic and adult-type globin mRNAs by sodium butyrate and trichostatin A in two murine interleukin-3-dependent bone marrow-derived cell lines. Blood, 92: 4383-4393, 1998.
12. Perrine, S. P., Faller, D. V., Swerdlow, P., Miller, B. A., Bank, A., Sytkowski, A. J., Reczek, J., Rudolph, A. M., and Kan, Y. W. Stopping the biologic clock for globin gene switching. Ann. N. Y. Acad. Sci., 612: 134-140, 1990.
13. Luo, R. X., and Dean. D. C. Chromatin remodeling and transcriptional regulation. J. Natl. Can. Inst., 91: 1288-1292, 1999.
14. Nan, X., Ng, H-H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., and Bird, A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (Lond.), 393: 386-389, 1998.
15. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., and Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet., 21: 103-107, 1999.
16. Breitman, T. R., and He, R. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Canc. Res., 60: 6268-6273, 1990.
17. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr., and Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (Lond.), 391: 811-814, 1998.
18. Warrell, R. P., Jr., He, L-Z., Richon, V., Calleja, E., and Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Can. Inst., 90: 1621-1625, 1998.
19. Gore, S. D., and Carducci, M. A. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin. Investig. Drugs, 9: 2923-2934, 2000.